Follow Us

       


"Like" us on Facebook

Clinical Trials

Disease or Condition
Cancer - Lung Cancer
Title
NSCLC (Stage IIIB/IV) 2nd Line
Description
ARCHER 1042: A Phase 2 study of Dacomitinib in advanced Non-Small Cell Lung Cancer (Post-Chemotherapy or select First Line Patients) to evaluate prophylactic intervention on Dermatologic and Gastrointestinal Adverse Events and Patient Reported Outcomes

Lung Cancer - A7471042/Pfizer
IRB Number
NCT01465802
Inclusion/Notes

For more information, please click here: http://www.clinicaltrials.gov/ct2/show/NCT01465802?term=NCT01465802&rank=1

Status
Closed to Enrollment
Principal Investigator
Julie Taguchi, MD
Contact Email
research@ccsb.org
Phone
(805) 898-2117

This is the fat footer - edit page 906 to add content.